Bourne Partners has advised Desitin Arzneimittel Gmbh (“Desitin” or the “Company”) on the sale of the Italian rights to Orfiril®-long (sodium valproate) to BiofuturaFarma S.p.A., a division of Sigma-tau, S.p.A., a leading Italian pharmaceutical company with annual sales in excess of $800 million.
